Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKaydihan, Nuri
dc.contributor.authorBESIII Collaboration
dc.date.accessioned2024-05-23T12:03:57Z
dc.date.available2024-05-23T12:03:57Z
dc.date.issued2024en_US
dc.identifier.citationGüzelöz, Z., Görken, İ. B., Aydın, B., Sert, F., Yalman, D., Parvizi, M., ... & Metcalfe, E. (2024). Evaluation of treatment outcomes and tolerability in older patients with rectal cancer treated with radiotherapy accompanied by the G-8 geriatric score: TROD13–003 multicenter study. Journal of Geriatric Oncology, 15(3), 101739.en_US
dc.identifier.issn18794068
dc.identifier.urihttps://doi.org/10.1016/j.jgo.2024.101739
dc.identifier.urihttps://hdl.handle.net/20.500.12294/4100
dc.description.abstractIntroduction: The choice of treatment for rectal cancer often differs in older and younger patients, with the rate of radiotherapy use lower among older adults. In our daily practice, when evaluating a frail older patient with rectal cancer, we usually choose to give less treatment. This may be due to concern that the patient will not be able to tolerate radiotherapy. The Geriatric 8 score (G8GS) is a guide to evaluating treatment tolerability as it relates to frailty in older adults with cancer. The aim of this study was to evaluate treatment outcomes and tolerability in older patients with rectal cancer treated with radiotherapy (RT) accompanied by G8GS. Materials and Methods: Patients aged 65 and older with stage I-III rectal adenocarcinoma who were treated with RT and had a G8 evaluation were included in this multicenter retrospective study. Prognostic factors related to G8GS were calculated using Chi-square and logistic regression tests and survival rates were calculated by the Kaplan -Meier test using the SPSS v24.0 software. All p -values <= 0.05 were considered statistically significant. Results: A total of 699 patients from 16 national institutions were evaluated. The median age was 72 years (range 65 -96), and the median follow-up was 43 (range 1190) months. Four hundred and fifty patients (64%) were categorized as frail with G8GS <= 14 points. Frail patients had higher ages ( p = 0.001) and more comorbidities (p = 0.001). Ability to receive concomitant and/or adjuvant chemotherapy rates were significantly higher in fit patients ( p = 0.002 and p = 0.001, respectively). No significant difference was observed in terms of grade 3-4 early and late toxicity for both groups. Cancer-related death was higher ( p = 0.003), and 5and 8-year survival rates were significantly lower (p = 0.001), in the frail group. Age and being frail were significantly associated with survival. Discussion: Radiotherapy is a tolerable and effective treatment option for older adults with rectal cancer even with low G8GS. Being in the frail group according to G8GS and having multiple comorbidities was negatively associated with survival. Addressing the medical needs of frail patients through a comprehensive geriatric assessment prior to radiotherapy may improve G8GS, allowing for standard treatment and increased survival rates.en_US
dc.language.isoengen_US
dc.publisherElsevier Ltden_US
dc.relation.ispartofJournal of Geriatric Oncologyen_US
dc.identifier.doi10.1016/j.jgo.2024.101739en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectELDERLY-PATIENTSen_US
dc.subjectCOLORECTAL-CANCERen_US
dc.subjectRADIATION-THERAPYen_US
dc.subjectSCREENING TOOLSen_US
dc.subjectPREOPERATIVE CHEMORADIOTHERAPYPen_US
dc.subjectROGNOSTIC VALUEen_US
dc.subjectRISKen_US
dc.subjectCOMPLICATIONSen_US
dc.subjectCHEMOTHERAPYen_US
dc.subjectMANAGEMENTen_US
dc.titleEvaluation of treatment outcomes and tolerability in older patients with rectal cancer treated with radiotherapy accompanied by the G-8 geriatric score: TROD13-003 multicenter studyen_US
dc.typearticleen_US
dc.departmentTıp Fakültesi, Dahili Tıp Bölümüen_US
dc.authorid0000-0002-3182-8623en_US
dc.identifier.volume15en_US
dc.identifier.issue3en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.institutionauthorKaydihan, Nuri
dc.authorwosidDUC-3235-2022en_US
dc.authorscopusid56491238500en_US
dc.identifier.wosqualityQ3en_US
dc.identifier.wosWOS:001220854300001en_US
dc.identifier.scopus2-s2.0-85187997936en_US
dc.identifier.pmid38492350en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster